ClinicalTrials.gg
RecruitingNCT06758830Updated May 11, 2026

Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.

A Phase 2/3 interventional study of Radiation Therapy and Chemoradiotherapy in Rectal Cancer, Total Neoadjuvant Treatment and Neoadjuvant Therapy, sponsored by National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos. Recruiting at 1 site in Lithuania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complications, quality of life, and survival rates of rectal cancer patients who have achieved a complete or near-complete clinical response to TNT, followed by a watch-and-wait approach, are comparable to those of patients who undergo surgery first. Additionally, the study aims to identify potential prognostic and predictive markers for rectal cancer and examine survival rates and factors influencing responses to chemoradiotherapy (CRT) or TNT.

The study is divided into two parts:

**Part One:** Participants with cT1N1, T2-T3 N0-1 rectal cancer, MRF-, and EMVI-, with surgery as one of the possible first-line treatment options, will be randomized into two groups. The experimental group will consist of participants receiving TNT, including CRT and consolidation chemotherapy (Ch). If these participants achieve a complete or near-complete clinical response, they will be observed using a watch-and-wait strategy, which is a non-operative approach. The control group will consist of participants who undergo surgical treatment initially.

**Part Two:** All participants with rectal cancer who have received CRT or TNT will be included. Additionally, participants diagnosed with rectal cancer who are scheduled for CRT or TNT but declined to participate in Part One or do not meet the inclusion criteria will also be included.

02

Conditions studied

  • Rectal Cancer
  • Total Neoadjuvant Treatment
  • Neoadjuvant Therapy
  • Radiotherapy
  • Chemotherapy
  • Organ Preservation
  • Radiotherapy Side Effect
  • Chemotherapy Side Effects
  • Chemoradiotherapy
  • Low Anterior Resection Syndrome
  • Quality of Life

Keywords

  • Rectal cancer
  • Total Neoadjuvant Treatment
  • Neoadjuvant therapy
  • Radiotherapy
  • Chemotherapy
  • Chemoradiotherapy
  • Organ Preservation
  • Radiotherapy Side Effect
  • Chemotherapy side effects
  • Quality of Lifte
  • Fatigue
  • Postoperative complications
  • Low Anterior Resection Syndrome
03

In context

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

This study's planned enrollment of 400 is above the median of 65 across 1,753 interventional studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part One

Inclusion Criteria:

  • Over 18 years of age.
  • Participants who agreed to participate in the study signed an form.
  • The (ECOG) score ranges from 0 to 2.
  • confirmed rectal adenocarcinoma.
  • Tumor up to 10 cm from the anus.
  • Magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the thorax and abdomen were performed to confirm the diagnosis.
  • cT1N1, T2-T3 N0 - 1, M0, MRF -, EMVI -.
  • Normal bone marrow function: blood leucocytes > 3.5 × 10⁹/l, neutrophils > 1.5 × 10⁹/l, > 100 × 10⁹/l.
  • Normal renal function: creatinine within 1,5 × normal.
  • Normal liver function: blood levels within 1,5 times normal, , ALT levels within 2,5 times the upper limit.

Exclusion Criteria:

  • Prior ST or Ch.
  • Participants who are not eligible for pelvic MRI.
  • Participants who have had a in the last 5 years, except for treatment for basal cell or squamous cell skin cancer or in situ cervical cancer.
  • ECOG status ≥ 3.
  • Distant detected.
  • Participants with uncontrolled therapeutic or psychiatric conditions.
  • Infectious diseases requiring antibiotic treatment.

Part Two

Inclusion Criteria:

  • Over 18 years of age.
  • Participants who agreed to participate in the study signed an informed consent form.
  • ECOG score between 0 and 2.
  • Pathological confirmed rectal adenocarcinoma.
  • Stage I to III rectal cancer confirmed.
  • The tumor is localized up to 12 cm from the anus.
  • Participants who refused to participate in the first part of the study or did not meet the inclusion criteria for the first part.
  • Participants have received preoperative CRT or TNT or are in the planning stages of treatment.

Exclusion Criteria:

  • New cancer two years after CRT.
  • Stage IV cancer before treatment.
  • Participants refusing to participate in the study or unable to sign the informed consent.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Part one. The first group: an experimental group - TNT, organ preservation.

    Participants in the experimental group will be treated with TNT - CRT plus consolidating Ch. Consolidation Ch lasts 12 weeks. The response to TNT will be assessed 4 to 5 weeks after the last cycle of Ch. Response assessment will be performed through digital examination, pelvic MRI, rectoscopy, and biopsy. Participants will be actively followed up and not treated after a complete or near-complete response. In case of non-response, participants will undergo surgery. If the participant is diagnosed with a near-complete clinical response and wishes to avoid surgery, the response is reassessed after 8 weeks. If there is no response, i.e., near-complete clinical response persists, the participant is offered surgery. Participants in the experimental group do not receive adjuvant treatment after TNT and surgery.

    Radiation: Radiation Therapy · Drug: Chemoradiotherapy · Drug: Consolidation Chemotherapy · Procedure: Surgery

  • Active comparator
    Part one. Second Group: a control Group - surgery

    In the control group, treatment will start with surgery. Following surgical treatment, adjuvant therapy may be provided for control group participants according to standard clinical practice if indicated.

  • Other
    Part two of the study

    In the second part of the study, investigators will prospectively collect and analyze the personal medical records of participants who have already received treatment with CRT or TNT. No new diagnostic or therapeutic approaches will be implemented; routine clinical practices for long-term follow-up will continue. For participants who have not received specific treatment and do not meet the inclusion criteria for the first part of the study, as well as those who declined to participate in that part, investigators will follow the routine clinical practices for investigation, treatment, and follow-up as long as they meet the inclusion criteria for the second part of the study.

    Other: Part two

Interventions

  • RadiationRadiation Therapy

    Radiation therapy (RT) is administered at a dose of 2 Gy per day for a total dose of 50 Gy delivered to the pelvis. This is done throughout 5 to 6 weeks.

  • DrugChemoradiotherapy

    Capecitabine: 825 mg/m² twice daily, prescribed 1-5 days per week, for 5 weeks during RT. Or Bolus 5-FU regimen: 5-fluorouracil (5-FU) 400 mg/m2/day intravenously, administered on days 1-4 and 33-35. Calcium folinate (folinic acid) 20 mg/m2/day intravenously on days 1-4 and 33-35.

  • DrugConsolidation Chemotherapy

    XELOX: Oxaliplatin 130 mg/m² (day 1) + capecitabine 1000 mg/m² (days 1-14), every 3 weeks for 4 cycles. Or FOLFOX: Oxaliplatin - 85 mg/m2 intravenously (2-hour infusion), drip for 1 day. Calcium folinate (folinic acid) - 400 mg/m2/d. intravenously (2-hour infusion), started on day 1. F(5-fluorouracil) - 400 mg/m2/d. intravenously (bolus), started on day 1. Repeat every 2 weeks for 6 times.

  • ProcedureSurgery

    Transabdominal Resection: Abdominoperineal resection, low anterior resection, or coloanal anastomosis using total mesorectal excision.

  • OtherPart two

    Standard treatment protocols and follow-up procedures are implemented in clinical practice.

  • OtherAdjuvant treatment

    If indicated, adjuvant therapy will be administered as usual in clinical practice.

06

What researchers measure

Primary outcomes

  1. Postoperative complications

    Assessed based on the Clavien Dindo classification.

    Time frame: From the start of treatment until 3 months after surgery.

  2. TNT toxicity

    Local and systemic toxicity and (or) side effects will be recorded according to the general terminology criteria for adverse events version 5.0 (CTCAE v5.0).

    Time frame: From the start of treatment until 3 months after TNT.

  3. Mortality rate

    Mortality after TNT or surgery.

    Time frame: From the start of treatment until 3 months after treatment.

  4. Quality of life

    Quality of life Will be assessed using scoring manual of European Organisation For Research And Treatment Of Cancer of CR29 (Colorectal).

    Time frame: From the start of treatment until 3 years after treatment.

  5. Low anterior resection syndrome rate.

    Assessed based on the LARS questionnaire

    Time frame: From the start of treatment until 3 years after treatment.

  6. Fatigue

    Fatigue will be assessed using scoring manual of the functional assessment of chronic illness therapy - fatigue (FACIT-F) questionnaire.

    Time frame: From the start of treatment until 3 years after treatment

  7. Complete clinical response rate

    Criteria for Complete Clinical Response DRE: * Smooth, flat scar * No nodularity Endoscopy: * Pale smooth scar with or without telangiectasia * No ulceration, nodularity, or mucosal irregularities * No stricture MRT: * Fibrotic, linear scar with low signal intensity on T2-weighted images * No diffusion restriction * No suspicious lymph nodes All of the criteria must be satisfied to define a complete clinical response.

    Time frame: 12 - 14 weeks after TNT

  8. Near-complete clinical response rate

    Near Complete Response DRE: \- Smooth induration or superficial minor mucosal irregularity Endoscopic: * Appearance with irregular small mucosal nodules, superficial ulceration, or mild persistent erythema MRI * Downstaging with or without residual fibrosis, small area of residual signal, and complete or partial regression of lymph nodes * Diffusion-weighted MRI with a small area of residual high signal intensity

    Time frame: 12 - 14 weeks after TNT

Secondary outcomes

  1. Rectal preservation rate

    Percentage of participants achieving complete or near-complete clinical response and rectal preservation using a "watch and wait" approach.

    Time frame: 3 years after TNT

  2. Local regrowth rate

    Percentage of participants with tumor regrowth after watch-and-wait when a complete or near-complete clinical response was achieved after TNT

    Time frame: 3 years after TNT

  3. Overall survival

    The time between enrolment and death from any cause.

    Time frame: 3 - 5 years.

  4. Disease-free survival

    The time between enrolment and the first documented disease progression, i.e. local recurrence or metastasis, or death from any cause.

    Time frame: 3 - 5 years.

  5. Local recurrence-free survival

    Local recurrence rates in participants who underwent surgery.

    Time frame: 3 - 5 years.

  6. Distant metastasis-free survival

    Incidence of distant metastases

    Time frame: 3 - 5 years.

  7. Stoma free survival

    Stoma-free survival is defined as the period after treatment during which the patient does not develop a stoma.

    Time frame: 3 - 5 years.

07

Study locations

1 of 1 sites recruiting
  • Nacional Cancer Institute
    Vilnius, 08660, Lithuania
    Recruiting
    • Ernestas Šileika, MD · Contacternestas.sileika@nvc.santa.lt · +37060950402
    • Audrius Dulskas, PhD · Contactaudrius.dulskas@gmail.com · +37067520094
    • Tomas Poškus, PhD · Principal investigator
    • Audrius Dulskas, PhD · Principal investigator
    • Ernestas Šileika, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2029, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Jan 6, 2025
StartActual
Jan 6, 2025
Primary completionEst.
Dec 27, 2029
CompletionEst.
Dec 27, 2029
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06758830
Lead sponsor
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Collaborators
Vilnius University, Tomas Poskus, Faculty of Medicine, Vilnius University, Vilnius University Hospital Santaros Klinikos, Research Council of Lithuania
Responsible party
Sponsor
First posted
Jan 6, 2025
Start date
Jan 6, 2025
Primary completion
Dec 27, 2029 (estimated)
Completion
Dec 27, 2029 (estimated)
Last update
May 11, 2026

Study contacts

Ernestas Šileika, MD
Contact
ernestas.sileika@nvc.santa.lt
+37060950402
Audrius Dulskas, PhD
Contact
audrius.dulskas@gmail.com
+370 675 20094
Tomas Poškus, PhD
study chair · Translational Health Research Institute, Faculty of Medicine, Vilnius University Ciurlionio str. 21, LT-03101 Vilnius
Audrius Dulskas, PhD
principal investigator · General and Abdominal Surgery and Oncology Department, National Cancer Institute, Vilnius, Lithuania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion